Importantly, disruption of this protein-protein interface—either by genetic deletion of the G9a pre-SET motif or by CtBP2 monomerization—abolished CtBP2-mediated stimulation of G9a, restored PTEN expression, and impaired tumor cell fitness, consistent with our functional data. The gene discussed is EHMT2; the disease is neoplasm.